期刊文献+

基质金属蛋白酶及其抑制剂对心房颤动心房结构重构的影响 被引量:8

Role of matrix metalloproteinase and tissue inhibitor of metalloproteinase in atrial structural remodeling in patients with atrial fibrillation
下载PDF
导出
摘要 目的研究心房颤动(房颤)患者心房组织基质金属蛋白酶(MMPs)及其抑制剂(TIMPs)的基因表达,探讨其与心房结构重构的关系。方法选取因风湿性心脏病接受换瓣手术的患者共50例,其中窦性心律组20例,房颤组30例,术前进行超声心动图检查。于开胸手术时取右心耳标本,分别进行免疫组化染色检查、荧光定量PCR方法检测标本中MMP-1、MMP-3、MMP-7、MMP-9及TIMP-1、TIMP-2、TIMP-3、TIMP-4表达。结果与窦性心律组比较,房颤组左右心房内径均显著扩大(P<0.01,P<0.01),心房组织中MMP-1表达有增加,但差异无显著性,MMP-3、MMP-7、MMP-9及TIMP-1、TIMP-2、TIMP-3、TIMP-4基因表达显著增加(均为P<0.01)。结论房颤患者心房组织MMPs及其TIMPs的表达改变与心房重构有关。 Objective To study the relationship between atrial structural remodeling and the expressions of matrix metalloproteinase (MMPs) and their tissue inhibitors (TIMPs) in atrial fibrillation (AF). Methods Biopsy samples of the right atrial appendages were collected from 20 patients with sinus rhythm and 30 with AF undergoing heart valve replacement surgery for rheumatic heart diseases. All the patients received echocardiographic examination preoperatively. MMP-1,-3,-7,-9 and TIMP-1,-2,-3,-4 protein expressions were detected by immunohistochemistry and RT-PCR. Results Compared with those in patients with sinus rhythm, the AF patients had significantly increased left and right atrial diameters and mRNA levels of MMP-3,-7,-9 and TIMP-1,-2,-3,-4 (P0.01). MMP-1 expression also showed an increase in AF patients, but the difference was no statistically significant from that in patients with sinus rhythm. Conclusion The expressions of MMP-1,-3,-7,-9 and TIMP-1,-2,-3,-4 increase in fibrillating atrial tissue, which may contribute to atrial structural remodeling and atrial dilatation in AF patients.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2010年第5期1160-1162,共3页 Journal of Southern Medical University
关键词 基质金属蛋白酶 组织型基质金属蛋白酶抑制因子 心房颤动 心房结构重构 matrix metalloproteinase tissue inhibitors of metalloproteinase atrial fibrillation atrial structural remodeling
  • 相关文献

参考文献10

  • 1朱慧,张薇,郭辰虹,张供,张维东,钟明,杨贵荣,葛志明,张运.心房肌基质金属蛋白酶-9和组织金属蛋白酶抑制因子-1表达改变对房颤心房重构机制的研究[J].中华医学杂志,2005,85(1):45-48. 被引量:30
  • 2Weberk T. Cardiac interstitum in health and disease: the fibrillar collagen network[J]. J Am Coll Cadiol, 1989, 13: 1637-52.
  • 3Raffetto JD, Rqouf A. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease [J]. Bioehem Pharmacol, 2008, 75: 346-59.
  • 4Tanaka A, Masuda H. IgE crosslinkage of F cepsilon receptor I induces both production and activation of matrix metalloproteinase-9 in mast cell[J]. Cell Immunol, 2004, 228(1): 66-75.
  • 5Xu J, Cui G, Esmailian F, et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation [ J ]. Circulation, 2004, 109 (3): 363-8.
  • 6Nakano Y, Niida S, Dote K, et al. Matrixmetallop roteinase-9 contributes to human atrial remodeling during atrialfibrillation [ J ]. JACC, 2004, 43(5): 818-25.
  • 7Kelly D, Khan S, Cockerill G, et al. Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodeling and all-cause mortality after acute myocardial infarction [J ]. Eur Heart Fail, 2008, 10: 133-9.
  • 8Bonnema DD, Webb CS, PenningtonWR, et al. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) [ J ]. J Card Fail, 2007, 13:530-40.
  • 9Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function [J]. Physiol Rev, 2007, 87: 1285-342.
  • 10申洪.免疫组织化学染色定量方法研究(Ⅲ)[J].中国组织化学与细胞化学杂志,1995,4(1):89-92. 被引量:398

二级参考文献11

  • 1申洪,陆药丹.免疫组织化学染色的定量方法研究[J].生物医学工程学杂志,1993,10(4):281-284. 被引量:126
  • 2Spinale FG, Coker ML, Bond BR, et al. Myocardial matrix degradation and metalloproteinase activation in the failing heart : a potential therapeutic target. Cardilvasc Res, 2000, 46:225-238.
  • 3Saharinen J, Hyytiainen M, Taipale J, et al. Latent transforming growth factor-beta binding proteins ( LTBPs ) structural extracellular nmtrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev, 1999, 10 : 99-117.
  • 4Peterson JT, Li H, Dillon L, et al. Evolution of matrix metalloproteinase and tissue inhibitor expression during heart failure progression int infracted rat. Cardiovasc Res, 2000, 46:307-315.
  • 5Nagahiro N, Kazuhiro Y, Yasushi S, et al. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Cardiovasc Res, 2003, 57:766-774.
  • 6Ducharme A , Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest, 2000, 106:55-62.
  • 7Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metallproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure . Nat Med, 1999, 5:1135-1142.
  • 8Borg TK, Burgess ML. Holding it all together: organization and function(s) of the extracellular matrix of the heart. Heart Failure,1993,8 : 230-238.
  • 9Li YY, Feldman AM, Sun Y, et al. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart.Circulation, 1998, 98 : 1728-1734.
  • 10Roten L, Nemoto S, Simsic J, et al. Effects of gene diletion of the tissue inhibitor of the matrix metalloproteinase-type 1 ( TIMP-1 ) on left ventricular geometry and function in mice. J Mol Cell Cardiol,2000, 32:109-120.

共引文献425

同被引文献78

引证文献8

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部